News of Note—MaxiVAX, PATH and more


Here is some other vaccine news of note for the week.

> International nonprofit organization PATH updated its brand and website. Release

> Swiss biotech MaxiVAX received an FDA Investigational New Drug Application for MVX-ONCO-1 and appointed T. Scott Johnson, M.D., a founder of The Medicines Company, as its chairman. Release (PDF) | Release (PDF)

> Pfenex received a milestone payment from Merck after the pharma giant started a phase 3 trial of its 15-valent pneumococcal vaccine. The candidate is subject to a 2007 agreement between the companies that allowed Merck to utilize the biotech's technology platform. Release

> Agenus named Sunil Gupta, M.D., as VP of regulatory and pharmacovigilance and Anna Wijatyk, M.D., as VP of clinical development. Release


Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.